Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Spectacular Earnings Numbers..Virtual Cash Cow

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Nov 10, 2023 10:35am

236 Views

Post# 35728270

RE:Spectacular Earnings Numbers..Virtual Cash Cow

So, it's worth $2.25 per share on its cash alone and no debt.
Over the past 3 quarters, it has been free cash flowing over $6 million cad per quarter.

Thats about $25 million or $1 per share being added in cash per year .

Yet our market cap is a miniscule $135 m.

This is easily a double from here and much more if they can acquire another drug or two from one of the large Pharmas.

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks